PRAXIS PRECISION MEDICINES INC (PRAX)
Health Care · Clinical-stage CNS precision medicine / rare neurological disorders · NASDAQ
A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms.
What PRAXIS PRECISION MEDICINES INC does
Praxis Precision Medicines is a clinical-stage CNS biopharmaceutical company focused on discovering and developing therapies for neurological disorders characterized by excitation-inhibition imbalance, particularly genetic epilepsies and movement disorders. The company operates two proprietary platforms—Cerebrum™, a small molecule discovery engine targeting ion channels and neuronal circuits, and Solidus™, an antisense oligonucleotide (ASO) platform using proprietary computational methods for gene modulation. It has four clinical-stage product candidates across its portfolio and employs translational biomarkers such as quantitative electroencephalography (qEEG) to guide development.
Themes: ["Genetic epilepsies / rare neurological disorders","CNS / neuronal excitation-inhibition balance","Precision medicine / patient stratification","Antisense oligonucleotides (ASO)","Ion channel modulation","Movement disorders","Developmental and epileptic encephalopathies (DEEs)","Autism spectrum disorders (genetics)","Intellectual disability (genetic)"]
Fundamentals
- Price$333.12 as of 2026-07-09 close
- Market cap$9.3B as of 2026-07-10
- 1-year return+612.1% as of 2026-07-09 close
- Net margin-2137.5% as of 2026-07-10
- ROE-43.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta2.80 as of 2026-07-10
Key risks (from latest filing)
["As an unprofitable, clinical-stage company with significant R&D burn ($77.9M in Q1 2026) and accumulated deficit of $1.2B, the company faces ongoing cash runway risk and may require additional capital raises or financing, which could dilute existing shareholders.","All product candidates are in clinical or preclinical stages with no approved medicines; failure to advance candidates through development, regulatory approval, or demonstrate clinical efficacy could materially harm the company's valuation and prospects.","Dependence on genetic precision medicine market adoption, patient recruitment into rare disease trials, and successful demonstration of the excitation-inhibition imbalance hypothesis across multiple indications creates execution and market validation risk."]
Competitors & peers
- Sage Therapeutics (SAGE)
- Biogen (BIIB)
- Ionis Pharmaceuticals (IONS)
- UCB Biopharma (UCB)
- Eisai
- GW Pharmaceuticals / Jazz Pharmaceuticals
- Marinus Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.